Skip to content

Esperion Therapeutics ESPR Professional service fees

Professional service fees at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$80.1M+23.2%
Operating income-$6.6M+70.2%
Net income-$25.2M+37.7%
EPS (diluted)-$0.10+52.4%

Balance sheet

See full
Cash & equivalents$156.2M+36.2%
Total debt$155.2M+6.1%
Total equity-$307.9M+27.8%
Total assets$462.5M+42.7%

Cash flow

See full
Operating cash flow-$27.7M-22.5%
CapEx$189.0K
Free cash flow-$27.9M-23.3%

Valuation

See full
Market cap$811.73M+283%
Enterprise value$810.81M+233%
P/S1.9×+1.1×

Profitability

See full
Operating margin18.1%+12.7pp
Net margin-34.8%+8.0pp
FCF margin-30.7%

Returns & leverage

See full
Return on equity-260.8%
Debt / equity0.8×
Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AccruedProfessionalFeesCurrent.

The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's professional service fees.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Esperion Therapeutics's professional service fees?
Esperion Therapeutics (ESPR) reported professional service fees of $3.02M in Q1 2026.
How has Esperion Therapeutics's professional service fees changed year-over-year?
Esperion Therapeutics's professional service fees decreased by 29.5% year-over-year, from $4.29M to $3.02M.
What is the long-term trend for Esperion Therapeutics's professional service fees?
Over 5 years (2020 to 2025), Esperion Therapeutics's professional service fees has grown at a 3.1% compound annual growth rate (CAGR), from $3.18M to $3.71M.